Clinical Trial Update: Evaluation of the Quality of the NovoSeven (rFVIIa) Tratment Practice at Rigshospitalet, Copenhagen University Hospital

View source ↗

Summary

A clinical trial update evaluating the use of NovoSeven (recombinant activated factor VII) for hemorrhage and shock at Rigshospitalet, Copenhagen University Hos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhage
• Shock

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Hemorrhage, Shock | Status: UNKNOWN